非小细胞肺癌全身治疗50年的进展
50 Years of progress in the systemic therapy of non-small cell lung cancer.
作者信息
Wakelee Heather, Kelly Karen, Edelman Martin J
机构信息
From the Stanford Cancer Institute, Stanford University, Stanford, CA; University of California, Davis Cancer Center, Sacramento, CA; University of New Mexico Cancer Center, Albuquerque, NM.
出版信息
Am Soc Clin Oncol Educ Book. 2014:177-89. doi: 10.14694/EdBook_AM.2014.34.177.
Abstract
Non-small cell lung cancer constitutes 85% to 90% of lung cancer and is the most common cause of cancer death. Over the past 50 years, substantial progress has been made in all aspects of lung cancer including screening, diagnostic evaluation, surgery, radiation therapy, and chemotherapy. This review focuses on the advances in systemic therapy during this half century.
摘要
非小细胞肺癌占肺癌的85%至90%，是癌症死亡的最常见原因。在过去50年里，肺癌在筛查、诊断评估、手术、放射治疗和化疗等各个方面都取得了重大进展。本综述重点关注这半个世纪以来全身治疗的进展。
相似文献
1
50 Years of progress in the systemic therapy of non-small cell lung cancer.非小细胞肺癌全身治疗50年的进展
Am Soc Clin Oncol Educ Book. 2014:177-89. doi: 10.14694/EdBook_AM.2014.34.177.
2
KEYNOTE-024: Unlocking a pathway to lung cancer cure?KEYNOTE-024：开启肺癌治愈之路？
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1777-1780. doi: 10.1016/j.jtcvs.2017.10.155. Epub 2017 Dec 23.
3
[Adjuvant or neoadjuvant chemotherapy in non-small cell bronchial cancers? Arguments in favor of choosing neoadjuvant chemotherapy].[非小细胞支气管癌的辅助化疗或新辅助化疗？支持选择新辅助化疗的论据]
Rev Pneumol Clin. 2002 Nov;58(5 Pt 2):3S33-6.
4
There and back again: An immunotherapy tale.往返之间：一个免疫疗法的故事。
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1771-1774. doi: 10.1016/j.jtcvs.2017.11.102. Epub 2017 Dec 23.
5
Adjuvant chemotherapy for elderly patients with non-small-cell lung cancer.老年非小细胞肺癌患者的辅助化疗
Asian Cardiovasc Thorac Ann. 2017 Jun;25(5):371-377. doi: 10.1177/0218492317714669. Epub 2017 Jun 7.
6
[Efficacy of postoperative adjuvant therapy for resected non-small cell lung cancer--an evidence-based review].[手术切除的非小细胞肺癌术后辅助治疗的疗效——一项基于证据的综述]
Gan To Kagaku Ryoho. 2006 Mar;33(3):300-6.
7
[Adjuvant chemotherapy in the early stages of non-small cell bronchial cancers].[非小细胞支气管癌早期的辅助化疗]
Rev Pneumol Clin. 2002 Nov;58(5 Pt 2):3S31-2.
8
[Second-line treatment of metastatic non-small cell lung carcinoma: What are the options today? What are the perspectives for tomorrow?].[转移性非小细胞肺癌的二线治疗：当今有哪些选择？未来有哪些前景？]
Rev Mal Respir. 2012 Jan;29(1):4-6. doi: 10.1016/j.rmr.2011.12.006.
9
[On ''Multimodal treatment of clinical non-small cell N2 bronchogenic carcinoma: what is the answer?''].论《临床非小细胞N2期支气管源性癌的多模式治疗：答案是什么？》
Arch Bronconeumol. 2007 Mar;43(3):183-4; author reply 184.
10
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.非小细胞肺癌的分子机制和靶向治疗包括免疫疗法。
Curr Cancer Drug Targets. 2019;19(8):595-630. doi: 10.2174/1568009619666181210114559.
引用本文的文献
1
[Comprehensive Analysis of the Expression, Prognosis and Function of TRAF Family Proteins
in NSCLC].[非小细胞肺癌中TRAF家族蛋白的表达、预后及功能的综合分析]
Zhongguo Fei Ai Za Zhi. 2025 Mar 20;28(3):183-194. doi: 10.3779/j.issn.1009-3419.2025.102.09.
2
Systemic treatment patterns and adherence to guidelines in Japanese patients with metastatic non-small cell lung cancer.日本转移性非小细胞肺癌患者的系统治疗模式及对指南的依从性
Future Oncol. 2025 Apr;21(9):1101-1111. doi: 10.1080/14796694.2025.2470611. Epub 2025 Feb 28.
3
Design, Synthesis, and Mechanistic Anticancer Evaluation of New Pyrimidine-Tethered Compounds.新型嘧啶连接化合物的设计、合成及抗癌作用机制评估
Pharmaceuticals (Basel). 2025 Feb 19;18(2):270. doi: 10.3390/ph18020270.
4
Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019-2024).用于克服非小细胞肺癌中C797S突变的新一代表皮生长因子受体酪氨酸激酶抑制剂（2019 - 2024年）
RSC Med Chem. 2024 Aug 30;15(10):3371-94. doi: 10.1039/d4md00384e.
5
Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment.肿瘤微环境图谱在单细胞相互作用水平上支持 EGFR 突变 NSCLC，并受 Unebuln 治疗的调节。
Cancer Res Commun. 2024 Mar 26;4(3):919-937. doi: 10.1158/2767-9764.CRC-23-0161.
6
Tumor Characteristics and Treatment Responsiveness in Pembrolizumab-Treated Non-Small Cell Lung Carcinoma.帕博利珠单抗治疗非小细胞肺癌的肿瘤特征及治疗反应性
Cancers (Basel). 2024 Feb 10;16(4):744. doi: 10.3390/cancers16040744.
7
Epigenetic regulation in lung cancer.肺癌中的表观遗传调控。
MedComm (2020). 2023 Oct 26;4(6):e401. doi: 10.1002/mco2.401. eCollection 2023 Dec.
8
Circulating hsa_circ_0072309, acting via the miR-100/ACKR3 pathway, maybe a potential biomarker for the diagnosis, prognosis, and treatment of brain metastasis from non-small-cell lung cancer.循环中的hsa_circ_0072309通过miR-100/ACKR3途径发挥作用，可能是非小细胞肺癌脑转移诊断、预后和治疗的潜在生物标志物。
Cancer Med. 2023 Sep;12(17):18005-18019. doi: 10.1002/cam4.6371. Epub 2023 Jul 26.
9
Celastrol elicits antitumor effects by inhibiting the STAT3 pathway through ROS accumulation in non-small cell lung cancer.雷公藤红素通过 ROS 积累抑制非小细胞肺癌中的 STAT3 通路来发挥抗肿瘤作用。
J Transl Med. 2022 Nov 12;20(1):525. doi: 10.1186/s12967-022-03741-9.
10
Molecular testing of cytology specimens: overview of assay selection with focus on lung, salivary gland, and thyroid testing.细胞学标本的分子检测：检测方法选择概述，重点是肺、唾液腺和甲状腺检测。
J Am Soc Cytopathol. 2022 Nov-Dec;11(6):403-414. doi: 10.1016/j.jasc.2022.08.002. Epub 2022 Aug 19.
本文引用的文献
1
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533.顺铂/依托泊苷/放疗后序贯多西他赛及贝伐单抗（NSC-704865）联合方案治疗不可切除的局部晚期Ⅲ期非小细胞肺癌的一项初步试验：SWOG S0533
Clin Lung Cancer. 2015 Sep;16(5):340-7. doi: 10.1016/j.cllc.2014.12.014. Epub 2015 Jan 9.
2
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.阿法替尼对比顺铂加吉西他滨用于治疗亚洲表皮生长因子受体突变阳性的晚期非小细胞肺癌患者的一线治疗（LUX-Lung 6）：一项开放标签、随机、III 期临床试验。
Lancet Oncol. 2014 Feb;15(2):213-22. doi: 10.1016/S1470-2045(13)70604-1. Epub 2014 Jan 15.
3
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.特泽莫替尼（L-BLP25）联合放化疗对比安慰剂治疗 III 期非小细胞肺癌（START）：一项随机、双盲、III 期临床试验。
Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.
4
Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma.TCGA 项目在鳞状细胞肺癌中的临床应用。
Oncology (Williston Park). 2013 Sep;27(9):899-906.
5
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.吉非替尼对比安慰剂用于完全切除的非小细胞肺癌：NCIC CTG BR19 研究结果。
J Clin Oncol. 2013 Sep 20;31(27):3320-6. doi: 10.1200/JCO.2013.51.1816. Epub 2013 Aug 26.
6
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.小分子抑制 KRAS-PDEδ 相互作用可损害致癌 KRAS 信号传导。
Nature. 2013 May 30;497(7451):638-42. doi: 10.1038/nature12205. Epub 2013 May 22.
7
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.基于 ERCC1 和 RRM1 表达的化疗与吉西他滨/卡铂对比治疗晚期非小细胞肺癌的随机国际 III 期临床试验。
J Clin Oncol. 2013 Jul 1;31(19):2404-12. doi: 10.1200/JCO.2012.46.9783. Epub 2013 May 20.
8
Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.前瞻性分层研究贝伐单抗或紫杉醇联合卡铂治疗非小细胞肺癌患者的随机 II 期研究β-3 微管蛋白状态。
J Clin Oncol. 2013 Jun 1;31(16):1990-6. doi: 10.1200/JCO.2012.45.3282. Epub 2013 Apr 15.
9
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.卡博替尼治疗 RET 融合阳性肺腺癌患者的疗效。
Cancer Discov. 2013 Jun;3(6):630-5. doi: 10.1158/2159-8290.CD-13-0035. Epub 2013 Mar 26.
10
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.非小细胞肺癌中 ERCC1 异构体表达与 DNA 修复。
N Engl J Med. 2013 Mar 21;368(12):1101-10. doi: 10.1056/NEJMoa1214271.
Zotero 插件